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a,b,c,d EgyptBackground: Psoriasis (Ps) is a common, relapsing, immune-mediated, inflammatory skin disorder of unknown
etiology. Ps is not single organ disease confined to the skin but it is systematic inflammatory condition analogous to
other inflammatory immune disorders which are known to have increased risk of heart disease. On other hand,
inflammation plays also an important role in the pathogenesis of atherosclerosis. So, there is striking similarity
between molecular and inflammatory pathway in Ps and atherosclerosis.
Aim of the work: Was to assess the presence of subclinical atherosclerosis in patients with Ps by using carotid
ultrasonography.
Patients and Methods: 60 patients with Ps were enrolled in this study after exclusion of traditional cardiovascular
risk factors and cardiovascular diseases (CVD). In addition, 20 age and gender matched healthy persons served as con-
trols. Patientswere classified according to Ps area and severity index (PASI) score into group I (20mild patients), group
II (20 moderate) and group III (20 severe). The average common carotid artery (CCA) intima media thickness (IMT),
internal diameter (ID) and arterial wallmass index (AWMI)weremeasured using high resolution B-mode ultrasound.
Results: Psoriatic patients showed statistically significant increase in CCA-IMT (P value 0.001), AWMI (P value
0.010) and significant decrease in ID (P value 0.001), as compared to controls.
Conclusion: Psoriasis patients could be suggested as a group with an increased atherosclerotic risk especially in
older ages with longer duration of Ps. The carotid IMT, ID and AWMI can identify patients with subclinical athero-
sclerosis who need special follow up to reduce cardiovascular morbidity and mortality.
Published by Elsevier B.V.
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Abbreviations
Ps psoriasis
CVD cardio-vascular diseases
PASI psoriasis area severity index
CCA common carotid artery
IMT intima media thickness
ID internal diameter
AWMI arterial wall mass index
SLE systemic lupus erythermatosus
RA rheumatoid arthritis
R redness
T thickness
S scalness
h head
u upper extremities
t trunk
i lower extremities
MHz mega hertz
GE general electric
MI myocardial Infarction
BMI body mass index
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Psoriasis (Ps) is a common, immune-mediated,inflammatory skin condition of unknown
etiology that requires lifelong treatment [1].
Advances in understanding the immunopatho-
genesis and genetics of Ps have shifted from single
organ disease confined to the skin to a systematic
inflammatory condition analogous to other
inflammatory immune disorders. Patients with
immune disorders, such as systemic lupus erythe-
matosus (SLE) or rheumatoid arthritis (RA), are
known to have increased risk of heart disease;
similarly, patients with Ps carry an excess risk of
heart disease [2]. Additionally, inflammation
plays an important role in the pathogenesis of
atherosclerosis [3,4]. There are therefore striking
similarities between molecular and inflammatory
pathways in psoriasis and atherosclerosis [2].
At present, a number of screening tests that
detect symptomatic patients at risk of atheroscle-
rosis are available, such as measurements of caro-
tid artery intima media thickness (IMT) [5] and
plaque by high resolution B mode ultrasound.
This is a useful, non-invasive surrogate marker
of macro vascular atherosclerosis that provides
early information on atherosclerosis in subclinical
stages of the disease. Increased IMT of the com-
mon carotid artery (CCA) is an indicator of gener-
alized atherosclerosis [6]. Carotid atherosclerosis
is associated with coronary atherosclerosis and
hence the incidence of carotid plaque or increased
IMT is higher in patients prone to coronary artery
disease [7,8].Patients and methods
This study was conducted on 60 psoriatic pa-
tients classified according to PASI score into
Group I (20 patients with mild psoriasis), Group
II (20 patients with moderate psoriasis) and Group
III (20 patients with severe psoriasis). The study
also included 20 disease-free subjects, with match-
ing age and gender who served as controls. All
subjects were recruited from the Outpatient Clinic
of Dermatology and Venereology Department,
Tanta University Hospital during the period of
June 2011 to June 2012. The Research Ethics Com-
mittee of the hospital (code No: 870/04/12) ap-
proved the study and informed written consent
was obtained from each participant.Exclusion criteria
Patients included in this study did not have other
dermatological or systemic diseases considered asrisk factors of atherosclerosis such as hypertension,
diabetes mellitus, SLE or RA. Study patients did not
have chronic hepatic or renal diseases, vascular
problems (such as CVD) or malignancies. The
study excluded psoriasis patients receiving anti-
psoriatic drugs, systemic (such as corticosteroid,
methotrexate or phototherapy) for at least 6 weeks
prior to the date of carotid ultrasonography. Preg-
nant or lactating women or women on contracep-
tives were also excluded, as were patients and
controls who gave a positive history of smoking.
Study participants were subjected to full his-
tory-taking, thorough general and dermatological
examinations, routine laboratory investigations
that included measurement of blood glucose lev-
els (fasting and 2 h postprandial); measurement
of lipid profile (cholesterol, triglycerides, high
density lipoprotein and low density lipoprotein);
complete blood picture, and hepatic and renal
function tests. Participants were then assessed
on psoriasis severity using the PASI score, which
evaluates the severity of psoriasis in relation to
three parameters: erythema (redness) (R), infiltra-
tion (thickness) (T) and desquamation (scaliness)
(S) [9]. Severity is rated for each index on a 0–4
scale (0 for no involvement, and up to 4 for severe
involvement). The body is divided into four re-
gions comprising the head (h), upper extremities
(u), trunk (t), and lower extremities (i). In each of
these areas, the fraction of total surface area af-
fected is graded on a 0–6 scale (0 for no involve-
ment; up to 6 for greater than 90% involvement).
The various body regions are weighed to reflect
their respective proportion of body surface area.
The composite PASI scores for each region by
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respective region, and then summing the four
resulting quantities; mathematically, this evalua-
tion is as follows: [9].
PASI ¼ 0:1ðRh þ Th þ ShÞAh þ 0:2ðRu þ Tu þ SuÞAu
þ 0:3ðRtþ Tt þ StÞAt þ 0:4ðRl þ Tl þ SlÞAl:
The PASI score is ranged from 1P 20Measurement of common carotid artery intima
media thickness, internal diameter and arterial
wall mass index
Carotid IMT was measured as a marker of sub-
clinical atherosclerosis to assess structural
changes in the vascular wall using a high resolu-
tion B-mode ultrasound with 7.5–10 MHz linear
vascular probe (Vivid 7, GE Vingmed Ultrasound).
Patients and controls were examined in supine
position with the neck extended and turned
slightly to the contralateral side. Both bilateral car-
otid arteries were scanned in both transverse and
longitudinal section to measure the IMT in the far
wall of the artery. The best images of the far wall
that could be obtained were used to determine
the CCA-IMT. Data was built into the machine.
CCAs were examined using posterior approach
by both transverse and longitudinal scans. Mea-
surements of the CCA-IMT and ID were taken at
three points on each side.
(1) CCA (10 mm before the bulb).
(2) Bulb (5–10 mm cranially to the start of the
bulb)
(3) Internal carotid artery column after the flow
divider.
The IMT was defined as a distance of more than
1.0 mm between the leading edge of the first echo-
genic line and the leading edge of the secondTable 1. Demographic data of studied groups.
Group I Group II
Age/year Range 19–45 28–48
Mean ± SD 30.4 ± 9.5 39.5 ± 6.3
Gender Male 8(40%) 12(60%)
Female 12(60%) 8(40%)
Duration/year Range 3–20 4–20
Mean ± SD 8.6 ± 2.1 10.9 ± 5.1
PASI score Range 1.8–9.7 10–19
Mean ± SD 6 ± 3.2 14.3 ± 3.3
Body mass index kg/m2 Range 22.5–29.6 24.9–29.7
Mean ± SD 26.5 ± 2.6 27.8 ± 1.8
Family history +VE 10(50%) 8(40%)
-VE 10(50%) 12(60%)
PASI = Ps area and severity index score.
* P highly significant 60.001.echogenic line. The first line represents the
luminal-intimal interface and the second line is
produced by the collagen-containing upper layer
of the adventitia close to the medial adventitial
interface. The maximum IMT, which is the highest
IMT value among the six segments studied, were
assessed according to sonographic criteria. IMT
was considered to be normal if 60.9 mm, while
values >0.9 mm were considered to be indicative
of thickened intima and value >1.3 mm was indic-
ative of atherosclerotic plaque [10]. The following
data were measured:
(1) Internal diameter at the end of diastole.
(2) Intima media thickness at the end of diastole.
(3) Arterial wall mass index (AWMI) was calcu-
lated using this equation: [10]
AWMI g=cmð Þ ¼ JI ID=2 þ IMTð Þ2  JI ID=2ð Þ2; where JI ¼ 22=7
Statistics
All data obtained were transferred to the statis-
tical package for Social Sciences version 15 (IBM
Co., New York, USA) for analysis. Data were sum-
marized using mean, standard deviation
(mean ± SD) using student’s t test. Comparison
between groups was made by using X2 test and
Fisher’s Exact Test for quantitative variables. Lin-
ear Correlation Coefficient was used for the detec-
tion of correlation between two quantitative
variables. Statistical significance was determined
at a level of p 6 0.05⁄; and p 6 0.001⁄ was consid-
ered highly significant.Results
Clinical results: the demographic characteristics
and disease profile of the patients are described in
Table 1.Group III Total Group IV f Test p Value
26–49 19–49 22–39 2.336 0.152
38 ± 9.1 35.9 ± 5.2 30 ± 5.9
12(60%) 32(53%) 12(60%) 3.176 0.311
8(40%) 28(47%) 8(40%)
4–19 3–20 – 1.345 0.632
10.6 ± 7.1 11.25 ± 6.95 –
21.7–43.6 1.8–43.6 – 22.36 0.001*
29.6 ± 6.2 18.49 ± 11.29 –
25.7–29.9 22.5–29.9 23.1–28.8 1.811 0.219
27.3 ± 2.8 27.3 ± 2.52 25.1 ± 3.5
8(40%) 26(43.3%) – 1.00 0.999
12(60%) 34(56.7%) –
Figure 1. Carotid artery intima media thickness 0.06 and ID 0.60 cm
in control subject. (Values 60.09 mm were considered to be normal).
Figure 2. Carotid artery intima media thickness 0.08 and ID 0.60 cm
in mild psoriatic patient.
Figure 3. Carotid artery intima media thickness 0.11 and ID 0.44 cm
in moderate psoriatic patient.
Figure 4. (a) Carotid artery intima media thickness 0.13 and ID
0.57 cm in severe psoriatic patient. (b) Carotid artery intima media
thickness 0.18 cm (atheromatous plaque in severe psoriatic patient.
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in Figs. 1–4b.
As regard the IMT, in Group I; it ranged from
0.036–0.135 cm with the mean (0.07 ± 0.03) cm; in
Group II it ranged from 0.045–0.12 cm with themean (0.09 ± 0.21) cm, while in Group III, it ranged
from 0.062–0.141 cm with the mean (0.10 ± 0.02) cm;
and in Group IV, it ranged from 0.03–0.079 cm with
the mean (0.05 ± 0.01) cm. Comparison between
patient groups regarding carotid IMT revealed
highly significant difference (P = 0.001). As for the
ID, in Group I, it ranged from 0.41–0.79 cm with
the mean (0.59 ± 0.09) cm; in Group II, it ranged
from 0.41–0.63 cm with the mean (0.51 ± 0.08) while
in Group III, it ranged from (0.49–0.60) cm with the
mean 0.54 ± 0.05 cm. In Group IV, it ranged from
0.418–0.63 cm with the mean (0.53 ± 0.07) cm.
Comparison between psoriatic patient groups
regarding carotid ID revealed a highly significant
difference (P = 0.001). As for the AWMI, in Group
I, it ranged from 0.077–0.292 mg/cm with the mean
(0.14 ± 0.06) mg/cm, while in Group II, it ranged
from 0.079–0.199 cm with the mean (0.15 ± 0.03)
mg/cm. In Group III, it ranged from 0.112–
0.479 mg/cm with the mean (0.23 ± 0.09) mg/cm,
and in Group IV, it ranged from 0.047–0.152 mg/
cm with the mean (0.09 ± 0.03) mg/cm. A compari-
son between psoriatic patient groups regarding
Table 2. Comparison between carotid ultrasonography results in the studied groups.
Group I Group II Group III Total Group IV f Test p Value
IMT/cm Range 0.036–0.135 0.045–0.12 0.062–0.14 0.036–0.14 0.036–0.079 11.442 0.001*
Mean ± SD 0.07 + 0.03 0.09 ± 0.21 0.10 ± 0.02 0.07 ± 0.02 0.05 ± 0.01
ID/cm Range 0.41–0.79 0.41–0.63 0.49–0.61 0.041–0.79 0.418–0.63 9.362 0.001*
Mean ± SD 0.59 ± 0.09 0.0.51 ± 0.08 0.54 ± 0.05 0.49 ± 0.18 0.53 ± 0.07
AWMI(g/cm) Range 0.077–0.292 0.079–0.199 0.112–0.474 0.077–0.48 0.047–0.152 8.963 0.010**
Mean ± SD 0.14 ± 0.06 0.15 ± 0.03 0.23 ± 0.09 0.18 ± 0.08 0.09 ± 0.03
IMT = Iintima media thickness, ID = Internal diameter, AWMI = Arterial wall mass index.
* P highly significant 60.001.
** P significant 60.05.
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(P = 0.010) (Table 2).
IMT in Group I showed a significant positive
correlation with BMI (Fig. 5) while IMT in GroupG RO UP :      1.00   m ild
BM I
323028262422
IM
T
.14
.12
.10
.08
.06
.04
.02
r. 0.243 
p. 0.019 
Figure 5. Intima media thickness in relation to body mass index in
Group I. atheromatous.
GRO UP:      3.00   severe
Age
6050403020
IM
T
.18
.16
.14
.12
.10
.08
.06
r.0.362
p.0.021
Figure 6. Intima media thickness in relation to age in Group III.III showed a significant positive correlation with
patient ages (Fig. 6), duration of disease (Fig. 7),
and PASI score (Fig. 8). The ID in Group III
showed significant positive correlation with BMIGROUP:      3.00   severe
Duration
403020100
IM
T
.18
.16
.14
.12
.10
.08
.06
r.0.425
p.0.008
Figure 7. Intima media thickness in relation to duration of disease in
Group III.
GROUP:      3.00   severe
PASI
50403020
IM
T
.18
.16
.14
.12
.10
.08
.06
p. 0.014
Figure 8. Intima media thickness in relation to psoriasis area and
severity index in Group III.
GROUP:      3.00   severe
.5
r.0.369
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age of patients and duration of disease. AWMI in
Group I showed a positive correlation with dura-GROUP:      3.00   severe
BMI
3230282624222018
ID
.7
.6
.5
.4
r. 0.396
p. 0.010
Figure 9. Internal diameter in relation to body mass index in Group III.
Figure 10. Arterial wall mass index in relation to duration of disease
in Group I.
GROUP:      1.00   mild
PASI
1086420
AW
M
I
.3
.2
.1
0.0
r. 0.324
p.0.042
Figure 11. Arterial wall mass index in relation to psoriasis area and
severity index in Group I.
Duration
403020100
AW
M
I
.4
.3
.2
.1
p. 0.010
Figure 12. Arterial wall mass index in relation to duration of disease
in Group III.
GROUP:      3.00   severe
BMI
3230282624222018
AW
M
I
.5
.4
.3
.2
.1
r. 0.296
p.0.042
Figure 13. Arterial wall mass index in relation to body mass index in
Group III.tion of disease (Fig. 10) and PASI score (Fig. 11),
while in Group III, AWMI showed a significant
positive correlation with duration of disease
(Fig. 12) and BMI (Fig. 13).Discussion
Carotid arteries are of particular interest to
investigators because they are easily accessible
to non-invasive examination by high resolution
B-mode ultrasonography which allows reliable,
easily accessible measurement of the carotid ar-
tery IMT. The latter is widely used to evaluate pre-
mature atherosclerosis in chronic inflammatory
diseases such as RA [11] and SLE [12]. The CCA-
IMT is an effective sonographic marker of early
atherosclerotic changes. It is a good indicator of
generalized atherosclerosis and coronary artery
disease providing early information on atheroscle-
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individuals at risk [13,14].
Ultrasonographic data of the current study
showed that the mean of IMT in psoriasis groups
was (0.07 ± 0.02) cm; and in control group mean
IMT was (0.05 ± 0.01) cm. A comparison between
psoriasis patients and controls regarding carotid
IMT revealed a highly significant difference
(P = 0.001). The mean IMT results of the present
our controls were similar to Grewal et al., [15]
and El-Mongy et al., [16].
The current study confirmed the findings from
previous studies that psoriasis was associated
with subclinical atherosclerosis by exhibiting an
increased carotid-IMT compared with healthy
controls [17–21]. Previous studies were performed
on chronic psoriasis patients, [16] or on both
psoriasis and PsA without other traditional risk
factors [22]. The results have shown that psoriasis
alone, PsA alone or both had increased CCA-IMT
compared with controls. Increased carotid IMT
was reported with higher frequency of coronary
heart disease in patients with chronic plaque pso-
riasis than no-psoriasis patients [23]. Moreover,
the increased risk of atherosclerosis was further
supported by Hahn et al., [24] who found that
even after controlling traditional cardiovascular
risk factors, psoriasis was conferred as an inde-
pendent risk for MI. CCA-IMT also serves as a risk
factor for MI and stroke in asymptomatic adults,
independent of traditional cardiovascular risk
factors [25].
In the present study, the correlation between
IMT and age of studied psoriatic patients revealed
a significant positive change in Group III. This
result was in agreement with that reported by
Kimhi et al., [17] Enany et al., [20] and Sahar
et al., [22] who showed that IMT correlated with
age as a conventional risk factor of atherosclerosis.
The present study revealed there was no signif-
icant correlation between IMT and gender of stud-
ied psoriatic patients. However, our study
revealed a significant positive correlation between
IMT and duration of disease in Group III, while no
significant correlation was found in Groups I and
II. These results were in agreement with various
studies [20,26–29] which showed that increased
cardiovascular risk, manifested as increased
carotid IMT, correlates with the duration of the
disease, suggesting that long standing inflamma-
tion is responsible for subclinical atherosclerosis.
These results were in contrast with the study
conducted by Sahar et al., [22] who reported no
correlation between IMT and duration of disease.
Also Balci et al., [19] failed to detect any associa-
tion between IMT and duration of disease,explaining this failure due to the relatively young
(mean age 38.5 years) of their patients.
The current study revealed a significant positive
correlation between IMT and BMI in Group I, but
not in Groups II and III. These results were in
agreement with Kimhi et al. [17] However, Sahar
et al. [22] showed no correlation between IMT
and BMI. In the this study, there was a significant
positive correlation between IMT and PASI score
in Group III, while there was no significant corre-
lation in Groups I and II. These results were in
line with the study conducted by El-Mongy et al.
[16]. Another study concluded that increased dis-
ease severity was associated with higher rate of
CVD [30]. In contrast, Kimhi et al. [18] and Sahar
et al. [23] showed no correlation between IMT
and PASI scores. The fact that PASI is not a stable
parameter may explain why these authors failed
to detect a significant association between subclin-
ical atherosclerosis indicators and PASI scores.
The most independent predictor of carotid IMT
in the present study was duration of disease
(R = 0.425, P = 0.008) followed by age (R = 0.362,
P = 0.021), PASI score (R = 0.326, P = 0.014) and
BMI (R = 0.243, P = 0.019). These results were in
contrast to El-Mongy et al. [16] who demonstrated
that age was the most important independent pre-
dictor of carotid IMT followed by PASI scores.
There is normal variation in the size of caliber or
diameter of carotid arteries from one population
to another, therefore ID was not as good an indica-
tor for subclinical atherosclerosis as IMT and
AWMI, but its role in this study was to estimate
the AWMI by equation, as previously discussed.
The mean of ID in psoriasis groups was
(0.49 ± 0.18) cm while in the control group it was
(0.53 ± 0.07) cm. Comparison between psoriatic
patients and the control group regarding carotid
ID revealed a highly significant difference.
Regarding the correlation between the ID and
clinical data of studied psoriatic patients there
was a significant negative correlation between ID
and age in Group III but no correlation was found
in either Group I or II. There was no correlation
between ID and all studied psoriatic groups in
relation to gender and PASI score. Also there
was a significant negative correlation between ID
and duration of disease in Group III, but there
was no correlation in either Group I or II. Correla-
tion of ID and BMI revealed a significant positive
correlation in Group III.
The AWMI ultrasonographic mean results for
all psoriatic groups were (0.18 ± 0.08) g/cm,
while in the control group, the mean was
(0.09 ± 0.03) g/cm. Comparison between psoriatic
patients and controls regarding carotid AWMI
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between AWMI in terms of age and gender,
revealed no significant correlation in all psoriatic
studied groups. Correlation between AWMI and
duration of disease showed a statistically signifi-
cant positive correlation in Group I and III, but
there was no significant correlation in Group II.
In addition, there was no significant correlation
between AWMI and BMI in Groups I and II, while
there was a significant positive correlation in
Group III. Also there was a significant positive
correlation between AWMI and PASI score in
Group I, while no significant correlation was
found in Groups II and III. The use of AWMI
and IMT are effective indicators in the detection
of early atherosclerotic changes in the artery, un-
like the use of plaque which is a late indicator of
atherosclerosis. To our knowledge, no reported
previous studies illustrate the association between
the ID and AWMI of CCA and the subclinical ath-
erosclerosis in psoriatic patients.
One study showed increased atherosclerosis
risk in psoriatic patients, particularly those with
moderate/severe disease, as evidenced by in-
creased expression of platelet CD62 compared
with healthy controls. Moreover, this study found
positive correlation between CD62 expression
PASI score [31].
Another study, aimed at assessing the associa-
tion between psoriasis and cardiovascular out-
comes, concluded that psoriatic patients with
predominantly mild disease from the general pop-
ulation are as likely to develop atherosclerosis and
cardiovascular events as subjects without psoria-
sis [32].
Finally, in the current study, psoriatic patients
showed evidence of subclinical atherosclerosis as
indicated by increased carotid IMT and AWMI
compared with matched controls. These changes
were more pronounced in older patients having
more severe disease as indicated by PASI score
and longer duration of the disease. All of these
results suggest that psoriasis itself is an indepen-
dent risk factor associated with subclinical athero-
sclerosis, whereas the presence of coexisting CVD
risk factors would aggravate this condition. This
leads us to speculate that early onset of athero-
sclerosis may be a characteristic feature of psoria-
sis similar to SLE and RA.Recommendations
Psoriasis patients could be suggested as a group
with an increased atherosclerotic risk especially in
older ages with more severe psoriasis and longer
duration of the disease. Older patients with severepsoriasis therefore need frequent follow-up to
reduce cardiovascular morbidity and mortality.References
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